newsfilter
← Latest News
Business Wire·

Ipsen Announces Withdrawal of Palovarotene NDA, Confirming Intention to Re-submit Following Additional Data Analyses

This follows ongoing dialogue with the U.S. FDA regarding the palovarotene NDA review, initiated in May 2021 Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen ((Euronext: IPN, OTC:IPSEY) today a